Novo Nordisk Cuts 9000 Jobs: A Strategic Shake-Up?
Update: 2025-09-10
Description
Novo Nordisk slashes 9,000 jobs, nearly 12% of its workforce, despite Ozempic and Wegovy success! Find out why the pharma giant is restructuring, bracing for a more competitive obesity market, and what this means for its future and investors. Will this bold move revive its stock and help it regain market dominance against rivals like Eli Lilly?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
